Poolbeg Pharma

POLB.L

Biotechnology · Healthcare

Price

8.30 GBp

+0.32 (+4.01%)

Market Cap

63.4M GBp

Exchange

London Stock Exchange

Winston Score

–

No score yet — Winston is napping.

We couldn’t gather enough financial data to score this stock reliably.

Share count rising — dilution

+20.5% over 4y

The company has issued more shares over this period, which dilutes each existing shareholder’s stake.

Diluted shares outstanding: 500.0M (2021) → 602.7M (2025)

Poolbeg Pharma is a small Irish clinical-stage biotechnology company that develops medicines to treat infectious diseases and conditions linked to the immune system. Its main focus is on drugs targeting severe influenza, respiratory illnesses, and inflammation-related conditions. The company does not yet sell any approved products — it is still running clinical trials to test whether its experimental treatments are safe and effective.

Poolbeg makes no revenue from product sales right now. Instead, it funds its research through equity raises and partnerships, which is typical for early-stage biotech companies. It is headquartered in Dublin, Ireland, and operates primarily in the UK and European markets, with a very small market cap of around $0.1 billion. The biggest risk the company faces is the high chance that its drug candidates could fail in clinical trials, which would make it difficult to raise more money and continue operations.

Winston Score History

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

Revenue data limited

EPS Growth

+29.6% YoY

YoY Growth Rate

EPS growth accelerating

R&D Spend

$2M/ year

↑ Rising (+10% vs prior year)

R&D investment increasing — building for the future

Insider Activity

32.4%ownership

Insiders own a meaningful stake in the company

Cash Runway

~5 months

$8M cash & investments

Quarterly Free Cash Flow

↓ Burn rate worsening

Short runway — potential dilution ahead through share issuance

Cash watch

Poolbeg Pharma has less than a year of cash at its current burn rate. Growth investors should watch for potential share dilution from future fundraising — that directly reduces your ownership.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Gross Margin

N/A

—

Data not available

Operating Margin

N/A

—

Data not available

ROCE

-44.9%

Weak — -44.9% return on capital

Negative ROIC means the business is losing money on every dollar invested in it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales YoY

N/A

—

Data not available

EPS YoY

N/A

—

Data not available

EPS Consistency

4/8 quarters

Earnings inconsistent quarter-to-quarter

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Cash Conversion

N/A

—

Data not available

FCF Margin

N/A

—

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

Debt / Equity

N/A

Data not available

Interest Cover

N/A

—

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

P/E Ratio (TTM)

N/M

—

Negative earnings — P/E not meaningful

P/E vs Forward

N/A

not available

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial